Pharsight

Pylarify is owned by Progenics Pharms Inc.

Pylarify contains Piflufolastat F-18.

Pylarify has a total of 4 drug patents out of which 0 drug patents have expired.

Pylarify was authorised for market use on 26 May, 2021.

Pylarify is available in solution;intravenous dosage forms.

Pylarify can be used as method of positron emission tomography (pet) in men with prostate cancer.

Drug patent challenges can be filed against Pylarify from 2025-05-26.

The generics of Pylarify are possible to be released after 09 June, 2037.

Application	Filing Date	Opposition Party	Legal Status
EP19214298A	2023-01-10	Telix Innovations S.A.	Granted and Under Opposition
EP18150494A	2021-09-30	Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg	Revoked
EP18150494A	2021-09-30	POLSERVICE KANCELARIA RZECZNIKOW PATENTOWYCH SP. Z O.O.	Revoked
EP18150494A	2021-09-23	Lewis Silkin LLP	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487129	PROGENICS PHARMS INC	Heterodimers of glutamic acid	Nov, 2027 (4 years from now)
US9861713	PROGENICS PHARMS INC	PSMA-binding agents and uses thereof	Jul, 2029 (6 years from now)
US8778305	PROGENICS PHARMS INC	PSMA-binding agents and uses thereof	Sep, 2030 (7 years from now)
US10947197	PROGENICS PHARMS INC	Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL	Jun, 2037 (14 years from now)